Sign in

Gonzalo Artiach

Senior Equity Analyst at Danske Bank

Gonzalo Artiach is a Senior Equity Analyst at Danske Bank, specializing in Nordic energy and renewables, with a primary focus on utility and renewable energy companies in the region. His coverage includes major players such as Ørsted, Vestas, and Fortum, where he provides investment insight and detailed equity research. Artiach began his career in financial analysis more than a decade ago and joined Danske Bank as an equity analyst after previously working in related roles within the European financial sector. He holds advanced credentials in financial analysis and is recognized for in-depth sector expertise, though specific success rates and rankings are not publicly available.

Gonzalo Artiach's questions to ASTRAZENECA (AZN) leadership

Question · Q3 2025

Gonzalo Artiach asked about Gefurulimab's recently presented data, noting its efficacy and safety signals appear in line with Ultomiris in MG. He inquired about the dynamics between these two products in MG and any future plans for Gefurulimab in other indications where Ultomiris is approved.

Answer

Chief Strategy Officer Marc Dunoyer explained that Gefurulimab's trial was conducted in earlier-stage patients than Ultomiris. He highlighted its convenient subcutaneous weekly administration (prefilled syringe or autoinjector), rapid onset, and sustained efficacy, but did not explicitly address plans for other indications.

Ask follow-up questions

Question · Q3 2025

Gonzalo Artiach asked about the dynamics between Gefurulimab and Ultomiris in myasthenia gravis (MG), given Gefurulimab's comparable efficacy and safety. He also inquired about future plans for Gefurulimab in other indications where Ultomiris is approved.

Answer

Chief Strategy Officer Marc Dunoyer explained that Gefurulimab's trial was conducted in earlier-stage MG patients compared to Ultomiris. He highlighted Gefurulimab's convenient, self-administered subcutaneous weekly dosing, rapid onset, and sustained efficacy as key differentiators, positioning it as a potential new first-line therapy.

Ask follow-up questions

Question · Q2 2025

Gonzalo Artiach of Danske Bank inquired about AstraZeneca's confidence in tozorakimab for COPD following mixed competitor data in the IL-33 space, and asked for details on the onselimab patient subgroup that showed positive results.

Answer

EVP of Biopharmaceuticals R&D, Sharon Barr, expressed confidence in tozorakimab, highlighting its differentiated profile that inhibits signaling through both ST2 and RAGE-EGFR pathways, which is important for COPD. CEO of Alexion, Marc Dunoyer, described the onselimab subgroup as a 'sizable minority' that saw a 'very meaningful' clinical benefit, but declined to provide further details ahead of a formal data presentation.

Ask follow-up questions

Question · Q4 2024

Gonzalo Artiach Castanon of Danske Bank inquired about launch expectations for Datroway in the TROPION-Breast01 setting, considering ADC sequencing with Enhertu. He also asked about the market opportunity for baxdrostat in primary aldosteronism.

Answer

David Fredrickson, EVP of Oncology, outlined that Datroway addresses a clear need in the fourth-line plus HR-positive setting and complements Enhertu, creating treatment options across the HER2 spectrum, including for patients post-ADC. Ruud Dobber, EVP of BioPharmaceuticals, noted that while primary aldosteronism is highly underdiagnosed, it represents a significant unmet need, affecting an estimated 5-8% of hypertensive patients.

Ask follow-up questions

Question · Q2 2024

Gonzalo Artiach Castanon asked for an update on FDA interactions for Dato-DXd ahead of its PDUFA date and sought a hypothesis for why Truqap failed in a triple-negative breast cancer study despite a strong launch in its approved indication.

Answer

EVP, Oncology R&D, Susan Galbraith, stated that discussions with the FDA for Dato-DXd are ongoing with no new updates. Regarding Truqap, she explained its mechanism is most effective where there is a reciprocal relationship with endocrine signaling, which is present in its approved indication and in prostate cancer, but not in the same way in triple-negative breast cancer. EVP, Oncology Business Unit, David Fredrickson, confirmed Truqap's launch is strong due to rapid biomarker adoption and good tolerability.

Ask follow-up questions

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%